FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase 2

Conditions: Acute Myeloid Leukemia in Remission
Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia
Minimal Residual Disease
Myelodysplastic/Myeloproliferative Neoplasm
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable

Interventions: Procedure: Allogeneic Bone Marrow Transplantation
Drug: Fludarabine Phosphate
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Treosulfan
Radiation: Total-Body Irradiation
Other: Laboratory Biomarker Analysis

First Posted Date: 2013-07-10

Last Posted Date: 2021-06-03

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 102

Registration Number: NCT01894477

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2

Completed

Conditions: Castration Levels of Testosterone
Castration-Resistant Prostate Carcinoma
Metastatic Prostate Carcinoma
Stage IV Prostate Cancer

Interventions: Biological: Glycosylated Recombinant Human Interleukin-7
Other: Laboratory Biomarker Analysis

First Posted Date: 2013-06-20

Last Posted Date: 2019-07-09

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 54

Registration Number: NCT01881867

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
UCSF Medical Center-Mount Zion, San Francisco, California, United States
🇺🇸
UCSF Medical Center-Mission Bay, San Francisco, California, United States

and more 13 locations

Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia

Phase 1

Completed

Conditions: Refractory Mantle Cell Lymphoma
Refractory Non-Hodgkin Lymphoma
CD19-Positive Neoplastic Cells Present
Recurrent Non-Hodgkin Lymphoma
Recurrent Chronic Lymphocytic Leukemia
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Small Lymphocytic Lymphoma
Refractory Acute Lymphoblastic Leukemia
Refractory Chronic Lymphocytic Leukemia

Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes

First Posted Date: 2013-05-31

Last Posted Date: 2022-05-25

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 204

Registration Number: NCT01865617

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children

Phase 2

Completed

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Acute Biphenotypic Leukemia
Acute Undifferentiated Leukemia
Adult Acute Lymphoblastic Leukemia in Remission
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Recurrent Adult Acute Lymphoblastic Leukemia
Refractory Childhood Acute Lymphoblastic Leukemia
Acute Leukemia of Ambiguous Lineage
Adult Acute Myeloid Leukemia in Remission
Childhood Acute Lymphoblastic Leukemia in Remission

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Methotrexate
Procedure: Peripheral Blood Stem Cell Transplantation
Biological: T Cell-Depleted Hematopoietic Stem Cell Transplantation
Drug: Tacrolimus
Drug: Thiotepa
Radiation: Total-Body Irradiation

First Posted Date: 2013-05-21

Last Posted Date: 2024-03-12

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT01858740

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Prevention of Ovarian Cancer in Women Participating in Mammography

Not Applicable

Completed

Conditions: Epithelial Ovarian Cancer

Interventions: Behavioral: genetic counseling

First Posted Date: 2013-05-10

Last Posted Date: 2016-01-28

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 458

Registration Number: NCT01851109

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Not Applicable

Completed

Conditions: Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Pure Erythroid Leukemia (M6b)
Chronic Myelomonocytic Leukemia
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Untreated Adult Acute Myeloid Leukemia
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Monocytic Leukemia (M5b)

Interventions: Drug: pravastatin sodium
Drug: idarubicin
Drug: cytarabine
Other: laboratory biomarker analysis

First Posted Date: 2013-04-15

Last Posted Date: 2017-11-17

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 24

Registration Number: NCT01831232

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women

Phase 4

Completed

Conditions: HIV

Interventions: Drug: Atripla or Stribild

First Posted Date: 2013-03-21

Last Posted Date: 2022-09-29

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 225

Registration Number: NCT01815580

Locations: 🇵🇪
Asociación Civil Impacta Salud y Educación, Lima, Peru

Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant

Phase 2

Completed

Conditions: Chronic Myelomonocytic Leukemia
Secondary Myelodysplastic Syndrome
de Novo Myelodysplastic Syndrome
Myelodysplastic Syndrome

Interventions: Drug: Azacitidine (AZC)
Drug: Decitabine
Other: Quality-of-Life Assessment

First Posted Date: 2013-03-18

Last Posted Date: 2024-02-15

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 50

Registration Number: NCT01812252

Locations: 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
Kaiser Permanente Washington, Seattle, Washington, United States
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

and more 1 locations